Oxford BioMedica looks to fill big orders

Oxford BioMedica (OXB) has secured £60 million and a new loan facility, addressing investor concerns and enabling strategic US expansion for commercial-scale manufacturing and fill-finish services. The gene therapy CDMO reported over 40% H1 revenue growth to £70-73 million and a robust £222 million order book, with management projecting 2026 revenues of £220-240 million, exceeding consensus, and 25-30% annual growth through 2028. This strong outlook prompted Panmure Liberum to raise its target price to 800p from 497p, noting that OXB trades at a discount to peers despite its accelerated growth trajectory.

Analysis

Oxford BioMedica (LSE:OXB) has significantly de-risked its investment profile by securing £60 million in new capital and a loan facility, directly addressing investor concerns over its capacity to fund expansion. This funding is earmarked for the strategic build-out of its US operations to include commercial-scale manufacturing and fill-finish services, a crucial step to serve the American market and mitigate potential tariff risks. The company exhibits strong operational momentum, evidenced by a July trading update flagging over 40% year-over-year revenue growth to £70-73 million for the first half, and a dramatic increase in order intake to £149 million from £56 million. The current order book of £222 million already covers full-year guidance, signaling robust demand. Furthermore, management has issued aggressive forward guidance, projecting revenues of £220-240 million for 2026—ahead of consensus—and sustained annual growth of 25-30% through 2028. This outlook is supported by analyst models from Panmure Liberum, which raised its price target to 800p from 497p, contingent on OXB securing a mix of late-stage and high-value commercial contracts. Despite a 33% stock appreciation in the past month, the shares still trade at a discount to specialist CDMO peers, which, coupled with its superior growth forecast, highlights a potential valuation anomaly.

Key Decisions for Investors

• Given the strengthened balance sheet, robust order book growth to £222 million, and an aggressive 2026 revenue target of £220-240 million, the current valuation discount to peers suggests a favorable risk/reward profile for accumulating or initiating a long position.
• Investors should closely monitor the company's ability to secure new late-stage and commercial contracts, as the successful conversion of just a few such programs is critical to validating the 25-30% annual growth trajectory through 2028.
• While the outlook is strong, execution risk centered on the US facility expansion remains a key factor; any delays in establishing commercial-scale manufacturing and fill-finish services could impact the ability to meet guidance and should be watched closely.
• The stock's recent 33% run-up indicates that positive sentiment is building, but with the price at 591p still significantly below the 800p analyst target, there may be further upside if execution on the strategic plan continues.